According to a recent article by The Manila Times, Design Therapeutics has reported encouraging interim results from its ongoing Phase 1/2 RESTORE-FA study, highlighting both clinical improvement and biomarker activity for DT-216P2, an investigational therapy for Friedreich ataxia (FA). The early findings, based on four weeks of treatment, suggest the drug may address the underlying genetic cause of the disease while improving patient symptoms.
DT-216P2 is a small-molecule candidate developed using the company’s GeneTAC® platform. It is designed to increase expression of frataxin (FXN), a protein deficient in FA due to GAA repeat expansions in the FXN gene. Restoration of FXN levels is considered a key therapeutic goal in this progressive neurodegenerative disorder.
Trial Design and Patient Population
The RESTORE-FA study is evaluating safety, pharmacokinetics, pharmacodynamics, and exploratory clinical outcomes across multiple dose levels. As of mid-May 2026, 16 patients with FA had completed four weeks of weekly intravenous therapy. Participants were evenly distributed across four dose cohorts ranging from 0.1 to 1 mg/kg.
Clinical Outcomes
Patients receiving the highest dose (1 mg/kg) demonstrated notable functional gains after four weeks. Mean improvement on the modified Friedreich’s Ataxia Rating Scale (mFARS)—a widely used measure of disease severity—was 6.4 points from baseline. Improvements were also observed in balance-related function, with a 2.7-point gain in upright stability scores.
Patient-reported fatigue, assessed using the PROMIS Fatigue Scale, improved by more than five points at both the end of treatment and two weeks later. This exceeds the commonly accepted threshold for clinically meaningful change, suggesting a tangible benefit from the patient perspective.
Importantly, improvements appeared dose-dependent, with higher dose levels associated with greater clinical benefit across multiple measures.
Biomarker Findings
The study also demonstrated robust biological activity. Increases in endogenous FXN were observed across several assays, including mRNA and protein levels in whole blood, as well as mRNA in muscle tissue. These findings indicate that DT-216P2 is active in both systemic circulation and affected tissues.
At the highest dose, whole blood FXN mRNA levels rose by approximately 65% from baseline, supporting the drug’s intended mechanism of action. The consistency of biomarker changes across tissues further strengthens confidence in target engagement.
Safety and Tolerability
DT-216P2 was generally well tolerated over the four-week treatment period. No serious adverse events or discontinuations were reported. Most side effects were mild to moderate in severity.
The most notable treatment-related events were transient increases in liver enzyme alanine transaminase (ALT) in three patients. These elevations were asymptomatic, not associated with bilirubin increases, and resolved without intervention. Investigators noted that such changes may reflect increased mitochondrial activity—a downstream effect of restoring FXN levels.
Implications and Next Steps
The combination of early clinical improvements and clear biomarker responses represents a promising signal in FA, a condition with limited treatment options. According to the company, these results may represent one of the first demonstrations of increased endogenous FXN alongside measurable clinical benefit in this patient population.
Based on the findings, Design Therapeutics plans to advance DT-216P2 toward registrational development. Further updates on the program’s regulatory pathway are expected later in 2026.
Conclusion
The initial data from RESTORE-FA suggest that DT-216P2 has the potential to modify disease biology while improving function and symptoms in patients with Friedreich ataxia. While larger and longer-term studies will be needed to confirm durability and safety, these early results position the therapy as a potentially significant development in the FA treatment landscape.
